Lars Gusch, CEO of Pharmacolog i Uppsala AB (publ) presented the company’s new strategic direction at Småbolagsdagarna, June 12th, 2023.
Pharmacolog paves the way for strong commercial development. By broadening the distribution network and introducing a SaaS model to lower the initial investment, more hospitals can implement quality control of compounded pharmaceuticals and thereby increase patient safety.
The live streamed event was arranged by Aktiespararna and the presentation (in Swedish) has been made available on the company website https://pharmacolog.com/investor-relations-2/.
For more information contact:
Lars Gusch, CEO
Email: lars.gusch@pharmacolog.com
Phone: +46 70-223 97 72
About Pharmacolog
Pharmacolog provides solutions and products that enhance work efficiency and safety when preparing injectable medication. Our goal is to help prevent medication errors and ensure maximum medication efficacy when treating patients with powerful yet potentially harmful injectable drugs. Pharmacolog’s products help staff at pharmacies and hospital wards minimize the risk of errors in the compounding process. Furthermore, by verifying that drugs and narcotics used in surgery have not been tampered with, our solutions also make a vital contribution to preventing drug diversion.
The following trademarks are owned and protected by Pharmacolog i Uppsala AB: Pharmacolog™-logo, DrugLog™, WasteLog™, PrepLog™ and Pharmacolog Dashboard™.
Further information regarding the company is available at https://pharmacolog.com/.
The company’s Certified Adviser is Mangold Fondkommission AB.
Release